Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats
In patients with Parkinson's disease, the therapeutic efficacy of l-DOPA medication is
gradually lost over time, and abnormal involuntary movements, dyskinesias, gradually …
gradually lost over time, and abnormal involuntary movements, dyskinesias, gradually …
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in
Parkinson's disease patients and represents a major limitation for the pharmacological …
Parkinson's disease patients and represents a major limitation for the pharmacological …
Serotonin transporter inhibition attenuates l‐DOPA‐induced dyskinesia without compromising l‐DOPA efficacy in hemi‐parkinsonian rats
C Bishop, JA George, W Buchta… - European Journal of …, 2012 - Wiley Online Library
Long‐term dopamine replacement therapy with l‐DOPA in Parkinson's disease often leads
to the development of abnormal involuntary movements known as l‐DOPA‐induced …
to the development of abnormal involuntary movements known as l‐DOPA‐induced …
Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease
K Kannari, K Kurahashi, M Tomiyama… - No to shinkei= Brain …, 2002 - europepmc.org
A rapid and excessive increase in extracellular dopamine (DA) after L-DOPA administration
is considered one of the major causes for L-DOPA-induced peak-dose dyskinesia …
is considered one of the major causes for L-DOPA-induced peak-dose dyskinesia …
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study
P Svenningsson, C Rosenblad, K af Edholm Arvidsson… - Brain, 2015 - academic.oup.com
In advanced stages of Parkinson's disease, serotonergic terminals take up l-DOPA and
convert it to dopamine. Abnormally released dopamine may participate in the development …
convert it to dopamine. Abnormally released dopamine may participate in the development …
Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia
Positron emission tomography (PET) imaging studies have shown that peak-dose
dyskinesia is associated to abnormally high levels of synaptic dopamine (DA) in the caudate …
dyskinesia is associated to abnormally high levels of synaptic dopamine (DA) in the caudate …
The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy
KL Eskow, V Gupta, S Alam, JY Park… - … Biochemistry and Behavior, 2007 - Elsevier
Dopamine (DA) replacement therapy with l-DOPA remains the standard pharmacotherapy
for Parkinson's disease (PD). Unfortunately, chronic l-DOPA treatment is accompanied by …
for Parkinson's disease (PD). Unfortunately, chronic l-DOPA treatment is accompanied by …
Serotonin–dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias
Appearance of dyskinesia is a common problem of long-term Levodopa (L-DOPA) treatment
in Parkinson's disease (PD) patients and represents a major limitation for the …
in Parkinson's disease (PD) patients and represents a major limitation for the …
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia
Dyskinesia (abnormal involuntary movements) is a common complication of l-DOPA
pharmacotherapy in Parkinson's disease, and is thought to depend on abnormal cell …
pharmacotherapy in Parkinson's disease, and is thought to depend on abnormal cell …
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function
l-DOPA-induced dyskinesia is a major complication of l-DOPA pharmacotherapy in
Parkinson's disease, and is thought to depend on abnormal cell signaling in the basal …
Parkinson's disease, and is thought to depend on abnormal cell signaling in the basal …